In patients with non-small-cell lung cancer (NSCLC), plasma levels of TGF-β are significantly elevated compared to individuals without lung cancer, and this elevation is closely associated with low survival rates [35]. This evidence concerns the gene TGFB1 and non-small cell lung carcinoma.